Press Releases

Biophytis announces receipt of Nasdaq Notice Biophytis announced that it has received written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) dated October 20, 2022, indicationg that, based upon a closing bid price of less than $1.00 per share for the Company’s American Depositary Shares (“ADSs”) for the prior 30 consecutive business deay period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2). The Notification Letter has no immediate effect on the listing of the ADSs, and they will continue to trade on The Nasdaq Global Select Market under the symbol “BPTS”. Pursuant to Nasdaq Listing Rule

Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference Biophytis made a presentation to investors on the 12th of September in New York, on the occasion of the 24th Global Investment Conference organised by the HC Wainwright bank, which is being held from 12 to 14 September 2022 in New York. During this oral presentation, Stanislas Veillet, CEO of Biophytis, gave an update on the company’s clinical results, presented the first results of the phase 2-3 COVA study in COVID-19-related respiratory failure and detailed the company’s next key steps. Stanislas Veillet, CEO of Biophytis, said: “I am very happy

Biophytis announces that on the 8th of September 2022 the Paris Court of Appeal rendered a decision in the case between Biophytis and Negma Group Ltd.

Biophytis released top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure

Results of the Combined General Meeting on June 21, 2022 All ordinary and extraordinary resolutions presented by the company have been adopted Biophytis announces the approval by a very large majority of all resolutions presented by the company and falling within the remit of the Combined General Meeting. Thanks to the mobilization of shareholders, the CGM could be held on second call with a quorum of more than 23% of the shareholders present or represented. The 26 resolutions presented by the company were approved at a very large majority and were comprising, as an ordinary resolution, the approval of the

Biophytis announced that it is presenting new preclinical efficacy data for its product Sarconeos (BIO101) in SMA (Spinal Muscular Atrophy) at the SMA Cure 2022 conference in Anaheim, California, USA on June 16-19, 2022. This oral presentation given by Dr. Cynthia Bézier and entitled: “COMBINATION OF BIO101 WITH ANTISENSE OLIGONUCLEOTIDE THERAPY DEMONSTRATES SYNERGISTIC BENEFICIAL EFFECTS IN SEVERE SMA-LIKE MICE” demonstrates, in a mouse model of SMA, the synergic effect of Sarconeos (BIO101) with antisense therapy. Stanislas Veillet, CEO of Biophytis, said: “We are very pleased to present this work to the SMA community. These new data highlight the full potential

Convening of Another Combined General Meeting at a Later Date Biophytis informs its shareholders that the combined Annual General Meeting (AGM) held on June 3, 2022 was unable to deliberate, as the required quorum was not reached. The shareholders taking part in the vote owned collectively 23 514 980 shares, or 15.45% of the share capital, and 16.19% of the voting rights. The 20% quorum necessary for holding an ordinary AGM on first call and the 25% quorum necessary for holding an extraordinary General Meeting on first call have not been reached. Therefore, in the absence of the quorum required